2011 biotech of the year , page-2

current partnerships with Roche & AstraZeneca.

$15m market cap > go figure


"The unique assets and skills of Phylogica have therefore been recognised by two of the largest and most highly regarded drug companies in the world."


"Last year the company said its commercial target was up to three partnerships with major pharmaceutical clients within 12 months. We have secured two alliances since December 2009 and remain on track for closing further partnerships in line with our guidance."


"The Phylogica team has found a number of these entirely new drug carriers. Most have never been indentified before by anyone. They have been manufactured, tested and sent to Roche for their review. We hope to have their response shortly and are optimistic they will confirm these exciting results and open new paths for new drugs."


"Phylogica is playing a very active role here in two ways. It has worked with one of Britain�s premiere cancer research groups, the MRC Hutchison Research Centre at the University of Cambridge, to assist them find new cancer causing triggers, and to plot the paths to create new drugs to deal with these triggers. This has been
a hugely successful collaboration, such that the UK team is now exploring fresh and expanded commercial opportunities with Phylogica."


"Another new partnership will further demonstrate the Phylogica magic, as its engine is put to a quite distinct use in another very serious disease."